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September 2010812 AbstractsHTN (P  .001) compared with normal. Despite this variation in comor-
bidities, hospital course, 30-day mortality, and morbidity in normal patients
were not significantly different compared with underweight, overweight, or
obese (P .05) patients. Subgroup analysis of LER, EVAR, and CAS again
revealed no significant difference.
Conclusions: Our data suggest that prevalence of abnormal BMI is
fairly common in patients undergoing endovascular procedures but does not
have significant impact on hospital course, 30-day mortality, and morbidity.
We can conclude that endovascular approach is safe in obese patients and
may be preferable to open procedures. Long-term effects of BMI on
outcome of endovascular surgical procedures is still to be established.
Modeling the Long-Term Effects of Early Endovascular Intervention
for Uncomplicated Type-B Dissection: The Effects of Late Aneurysm
Formation
Karl A. Illig, MD, Kate Young, PhD, David L. Gillespie, MD, Jason K. Kim,
MD, Dustin Fanciullo, MD, Peter Knight, MD, and Michael J. Singh, MD,
University of Rochester, Rochester, NY
Objectives:Recent data show no differences in survival to 2 years when
chronic (2 to 52 weeks from symptom onset) uncomplicated type B aortic
dissection is treated medically or with thoracic endovascular repair (TEVR).
The high rate of late aneurysmal degeneration, however, coupled with the
high mortality and paralysis rate of this entity, is critical to include in any
analysis of the relative effectiveness of these two treatments.
Methods: We constructed a Markov model including the possible
outcomes of a thoracoabdominal aneurysm (TAAA) repair (death, alive with
paralysis, or alive intact). We used as input 2-year outcomes from the
Investigation of Stent Grafts in Aortic Dissection (INSTEAD) trial, a
prospective randomized trial of TEVR vs medical management in patients
with uncomplicated type B dissection. The chances of developing a TAAA
were derived from observational studies of both medically and intervention-
ally treated dissections in the existing literature, with the artificial assumption
made that rates were linear from years 3 to 8. Calculated survival (life-years
gained) was derived using TreeAge.
Results: INSTEAD documented a 95.6% 2-year survival despite a
20.6% rate of crossover to TEVR or open surgical repair in patients random-
ized to medical treatment, whereas survival in those randomized to TEVR
was 88.9%. Existing literature suggests that 33% of medically managed
patients will develop TAAA 8 years after dissection, but that this rate may be
only 5% after TEVR. Assuming that the ratio of late TAAA formation in the
medical vs TEVR groups is 5:1, for a 60 year-old cohort, 21.7 years are
gained after early TEVR compared with 17.2 years after medical manage-
ment alone. Factoring in paralysis and stroke, early TEVR results in 12.4
quality-adjusted life years compared with 11.3 for medical management
alone. Medical management does not become the preferred option until the
rate of TAAA formation in the medical vs TEVR groups drops to 1.9:1.
Conclusions: Although short-term (2-year) results are not different
whether uncomplicated type B dissection is treated with medical manage-
ment or TEVR, when the roughly fivefold increased risk of late TAAA
formation in medically-treated patients is factored in, an additional 4.5 years
of life are gained by early TEVR. The advantage of early TEVR is not lost
until the risk of TAAA formation is only halved.
Should Endovascular Aneurysm Repair Be Offered to Patients with
Short Infrarenal Necks?
Neal S. Cayne, MD, Sean Raj, BS, Todd L. Berland, MD, Caron R.
Rockman, MD, Thomas S. Maldonado, MD, Mark A. Adelman, MD,
Patrick J. Lamparello, MD, Glenn S. Jacobowitz, MD, Thomas S. Riles,
MD, Firas Mussa, MD, and Frank J. Veith, MD, New York University, New
York, NY
Objectives: One of the most important determinants for successful
endovascular repair of abdominal aortic aneurysms (EVAR) is adequate
infrarenal aortic neck length. We reviewed our experience with EVAR in
patients with short (15 m) infrarenal necks focusing on the incidence,
treatment, and midterm outcome of proximal attachment site endoleaks.
Methods: Between December 2000 and July 2008, 92 patients were
identified who had an infrarenal aortic neck length of 15 mm. These
patients were considered high risk for open surgery. All patients with Ancure
grafts (n  37) were excluded, leaving 55 patients for analysis. The mean
neck length was 9.6  2.7 mm (range, 4-14 mm) with a mean preoperative
aneurysm size of 6.2  1.2 cm. Endovascular grafts implanted in patients
with short infrarenal necks were 65% Zenith (n  36), 24% AneuRx (n 
13), and 11% Excluder (n  6). Mean follow-up was 21  18 months
(range, 1-72 months).
Results: Five proximal endoleaks were recognized on the first comple-
tion angiogram in the operating room. Four of these endoleaks were sealed
intraoperatively with balloon angioplasty and/or proximal extension cuffs.
One patient had a persistent small type I endoleak intraoperatively, despite
the placement an extension cuff and Palmaz stent. This leak resolved
spontaneously after 1 month. Two patients developed delayed type I en-doleaks. One patient developed the endoleak 1 month after the procedure
and was successfully treated with an extension cuff. The second patient
presented at 63 months after the procedure with a contained rupture from a
delayed type I leak. This patient was successfully treated with an aortouniiliac
device. In both of these patients, AneuRx grafts were originally implanted.
The overall incidence of delayed postoperative type I endoleaks was 2 of
55 (4%). Mean aneurysm size on follow-up decreased to 5.0  1.3 cm.
Overall mortality was 14% (8 of 55) during the follow-up period; however,
there were no additional ruptures or aneurysm-related deaths.
Conclusions:Our data suggest that acceptable midterm results can be
achieved when performing EVAR in high-risk patients with short (15mm)
infrarenal necks. Therefore, AAA patients with severe comorbidities and
short infrarenal neck lengths should not be denied EVAR based on short
neck length alone. Longer-term data will be needed to determine durability
of EVAR in these patients.
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Objective: Endovascular repair of intact abdominal aortic aneurysms
(EVAR) has been shown to decrease morbidity and resource utilization com-
pared with open repair (open). However, the utility of EVAR for the repair of
ruptured abdominal aortic aneurysms (RAAA) remains unknown. This study
used the Medicare database to evaluate trends in RAAA volume and compared
outcomes of open and EVAR repair of RAAA in contemporary practice.
Methods: Patients treated for RAAAwere identified by ICD-9 Code in
the Medicare database from 2004-2007 and stratified into four cohorts:
open repair (OR), EVAR, those who underwent exploratory laparotomy
(Exlap), and died, and those with no surgical treatment (NoOR) who died
24 hours of presentation. The OR and EVAR cohorts were then evaluated
for perioperative mortality, hospital length of stay, and cost data; long-term
survival was determined with Kaplan-Meier.
Results:During the study period, 15,684 patients were identified with
RAAA. Rupture incidence steadily decreased over time, and the frequency of
EVAR increased (P .0001; Table). The groups differed in age (76.8 years
EVAR vs 76.2 years OR, P  .008) and end-stage renal disease (3% EVAR
vs 1% OR, P .0001), but not by male gender (76% EVAR vs 74% OR, P
.29). Perioperative mortality was lower with EVAR (30% vs 44% OR, P 
.0001). The EVAR group had a shorter hospital length of stay (10.2 vs 13
days OR, P  .0001) and fewer ICU days (5.9 vs 8.6 days OR, P  .0001)
than the OR cohort. The 3-year survival was 42% EVAR and 38% OR (P 
.0001; significance likely due to the early death rate in the OR group). The
medical supply/device charge was higher with EVAR ($33,340 vs $13,090
OR, P  .0001) but the intensive care charges ($16,575 vs $21,864 OR, P
 .0001) and the Medicare payments ($33,504 vs $35,820 OR, P  .02)
were higher with OR.
Conclusions: The incidence of RAAA continues to decrease in the
endovascular era, and EVAR is being used more frequently in RAAA. EVAR
offers a significant perioperative survival benefit over open repair without
adding additional cost to the initial hospital stay. However, the 5-year
survival is equal between the two groups.
Should the Vascular Surgeon Continue Performing Temporal Artery
Biopsies?
Sotero E. Peralta, Xin Li, Richard Schutzer, MD, Mihai Rosca, MD, Mark
Kissin, M and Kambhampaty Krishnasastry, MD, North Shore–Long Island
Jewish, Lake Success, NY
Objective: Giant-cell arteritis is one of the most common vasculitic
disorders that a vascular surgeon encounters during daily practice. Accord-
ing to American College of Rheumatology guidelines, the diagnosis can be
established on clinical findings without the need of a pathologic specimen.
We examined the current experience of vascular surgery service performing
temporal artery biopsies.Methods: We retrospectively reviewed the cases in which the vascular
surgery service performed a temporal artery biopsy between January 1, 2008,
